ReviewFrontiers in cardiovascular medicine2020
Natural Biomaterials for Cardiac Tissue Engineering: A Highly Biocompatible Solution.
Review in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Chitosan-Based Scaffolds for the Treatment of Myocardial Infarction: A Systematic Review.Molecules (Basel, Switzerland) · 2023Pooled it
- Bacterial Nanocellulose Hydrogels as a Next-Generation Biomaterial for Cardiac and Vascular Tissue Engineering: Structural, Biological, and Translational Perspectives.Gels (Basel, Switzerland) · 2026Review
- Coarse-grained Martini 3 model for collagen fibrils.Biophysical journal · 2026Article
- Innovations in skeletal muscle regeneration: from physiology to bioengineering approaches for repair and restoration.Frontiers in physiology · 2026Review
- New frontiers in porcine atrioventricular node decellularization: preserving extracellular matrix architecture for biological scaffolds.Frontiers in bioengineering and biotechnology · 2026Article
- Sodium alginate-encapsulated Colchicum nanoparticles attenuate TNF-α and NF-κB signaling in macrophages: A novel therapeutic strategy for rheumatoid arthritis.Inflammopharmacology · 2026Article
- Being a Target for Glycation by Methylglyoxal Contributes to Therapeutic Efficacy of Injectable Collagen Hydrogels Post-Myocardial Infarction.Gels (Basel, Switzerland) · 2025Article
- Toward strategies to advance the conductive properties of hydrogel formulations for cardiac tissue engineering.iScience · 2025Review
- Melt electrowritten medium chain length polyhydroxyalkanoate cardiac patches for Post-MI cardiac regeneration.Materials today. Bio · 2025Article
- [Advances in hydrogel drug delivery systems for myocardial infarction treatment].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Recent Advances in the Development and Application of Cell-Loaded Collagen Scaffolds.International journal of molecular sciences · 2025Review
- Advances in Conductive Biomaterials for Cardiac Tissue Engineering: Design, Fabrication, and Functional Integration.Polymers · 2025Review
- Bioprinting approaches in cardiac tissue engineering to reproduce blood-pumping heart function.iScience · 2025Review
- Structural and Thermal Characterization of BluephaMaterials (Basel, Switzerland) · 2024Article
- Enhancing the Potential of PHAs in Tissue Engineering Applications: A Review of Chemical Modification Methods.Materials (Basel, Switzerland) · 2024Review
- Injectable Hydrogels in Cardiovascular Tissue Engineering.Polymers · 2024Review
- Macrophages enhance contractile force in iPSC-derived human engineered cardiac tissue.Cell reports · 2024Article
- Advancing cardiac regeneration through 3D bioprinting: methods, applications, and future directions.Heart failure reviews · 2024Review
- Review
- Exosomes Secreted by Wharton's Jelly-Derived Mesenchymal Stem Cells Promote the Ability of Cell Proliferation and Migration for Keratinocyte.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
Cardiovascular diseases (CVD) constitute a major fraction of the current major global diseases and lead to about 30% of the deaths, i.e., 17.9 million deaths per year. CVD include coronary artery disease (CAD), myocardial infarction (MI), arrhythmias, heart failure, heart valve diseases, congenital heart disease, and cardiomyopathy. Cardiac Tissue Engineering (CTE) aims to address these conditions, the overall goal being the efficient regeneration of diseased cardiac tissue using an ideal combination of biomaterials and cells. Various cells have thus far been utilized in pre-clinical studies for CTE. These include adult stem cell populations (mesenchymal stem cells) and pluripotent stem cells (including autologous human induced pluripotent stem cells or allogenic human embryonic stem cells) with the latter undergoing differentiation to form functional cardiac cells. The ideal biomaterial for cardiac tissue engineering needs to have suitable material properties with the ability to support efficient attachment, growth, and differentiation of the cardiac cells, leading to the formation of functional cardiac tissue. In this review, we have focused on the use of biomaterials of natural origin for CTE. Natural biomaterials are generally known to be highly biocompatible and in addition are sustainable in nature. We have focused on those that have been widely explored in CTE and describe the original work and the current state of art. These include fibrinogen (in the context of Engineered Heart Tissue, EHT), collagen, alginate, silk, and Polyhydroxyalkanoates (PHAs). Amongst these, fibrinogen, collagen, alginate, and silk are isolated from natural sources whereas PHAs are produced via bacterial fermentation. Overall, these biomaterials have proven to be highly promising, displaying robust biocompatibility and, when combined with cells, an ability to enhance post-MI cardiac function in pre-clinical models. As such, CTE has great potential for future clinical solutions and hence can lead to a considerable reduction in mortality rates due to CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.